Effects of Procyanidine on Semen Parameters and DNA Fragmentation Index During Cryopreservation of Abnormal Human Semen Samples

February 24, 2018 updated by: E.M. Kolibianakis, Aristotle University Of Thessaloniki

Effects of Procyanidine on Semen Parameters and DNA Fragmentation Index During Cryopreservation of Abnormal Human Semen Samples: a Prospective, Double-blind Trial

Cryopreservation is the storage of biological material at subzero temperatures at which biochemical processes of cell metabolism and the biochemical reactions that lead to cell death are slowed, interrupted or stopped.Many investigators have focused on the use of antioxidants in the freezing media to reduce the negative effects of reactive oxygen species(ROS) on spermatozoa and in this context addition of vitamin E to cryoprotective medium enhanced the post-thaw sperm motility and preserved sperm DNA integrity , superoxide dismutase (SOD) and catalase (CAT) were added to boar spermatozoa freezing media and they not only increased sperm motility and viability but also decreased post-thaw ROS generation which led to improvement in results of in vitro fertilizing with thawed spermatozoa.However, the impact of in vitro addition of proanthocyanidins to human semen before cryopreservation on post-thawing semen parameters, DFI has not been studied yet. The research question evaluated in the current study was whether semen samples of infertile men supplemented or not with procyanidine before cryopreservation, differ in post-thawing semen parameters and sperm DNA fragmentation index (DFI).

Study Overview

Study Type

Interventional

Enrollment (Actual)

50

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Thessaloniki, Greece, 54603
        • Stratis Kolibianakis

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

16 years to 48 years (Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

Male

Description

Inclusion Criteria:

Infertility defined as:

  • At least twelve (12) months of non-achieving pregnancy despite unprotected sexual intercourse or six (6) months, if the female is > 35 years of age AND
  • At least two (2) semen analyses with at least one abnormal parameter (sperm concentration, motility and morphology), according to WHO 2010 criteria.
  • Not on any type of infertility treatment for the last three (3) months
  • Sperm concentration > 8 x 106/ml and semen volume at least 2.5 ml for technical reasons.
  • Normal hormonal profile (TSH, FSH, LH, total testosterone, prolactin)
  • Seminal white blood cells < 1 x 106/ml
  • No abnormalities in scrotal ultrasound.

Exclusion Criteria:

  • Underlying genetic cause of infertility
  • History of undescended testis (cryptorchidism)
  • History of orchidectomy
  • History of testicular cancer
  • History of severe cardiac, hepatic or renal disease.
  • History of endocrine disease (primary or secondary hypogonadism, hyperprolactinemia, thyroid disease, pituitary or adrenal disease)
  • History of epididymo-orchitis, prostatitis, genital trauma, testicular torsion, inguinal or genital surgery
  • History of systemic disease or treatment during the last three (3) months
  • Positive sperm culture for Chlamydia or Ureaplasma urealyticum
  • Female infertility factors
  • Body mass index (BMI) > 30 kg/m2
  • Participation in another interventional study and a likelihood of being unavailable for follow-up.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Basic Science
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Quadruple

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
No Intervention: Control group
Experimental: procyanidine group
Natural antioxidant

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Progressive sperm motility
Time Frame: 3 Hours after ejaculation and immediately after thawing with or without Procyanidine
percentage (%) of decrease
3 Hours after ejaculation and immediately after thawing with or without Procyanidine

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Sperm DNA fragmentation index
Time Frame: 3 Hours after ejaculation and immediately after thawing with or without Procyanidine
percentage (%) of increase
3 Hours after ejaculation and immediately after thawing with or without Procyanidine
Sperm morphology
Time Frame: 3 Hours after ejaculation and immediately after thawing with or without Procyanidine
percentage (%) of decrease
3 Hours after ejaculation and immediately after thawing with or without Procyanidine
Sperm vitality
Time Frame: 3 Hours after ejaculation and immediately after thawing with or without Procyanidine
percentage (%) of decrease
3 Hours after ejaculation and immediately after thawing with or without Procyanidine

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

August 3, 2017

Primary Completion (Actual)

January 10, 2018

Study Completion (Actual)

February 5, 2018

Study Registration Dates

First Submitted

February 20, 2018

First Submitted That Met QC Criteria

February 24, 2018

First Posted (Actual)

March 2, 2018

Study Record Updates

Last Update Posted (Actual)

March 2, 2018

Last Update Submitted That Met QC Criteria

February 24, 2018

Last Verified

February 1, 2018

More Information

Terms related to this study

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Spermatogenesis and Semen Disorders

Clinical Trials on procyanidine

3
Subscribe